There are currently two ongoing phase I trials to test the PK, pharmacodynamics, safety, and clinical efficacy of ivosidenib in patients with R/R AML with IDH1 mutations (NCT02074839, NCT04176393). The gene discussed is IDH1; the disease is acute myeloid leukemia.